Acrobot Co. Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Acrobot Co. Ltd.
Private investors in orthopedic companies still are backing traditional and large joint companies, but soft tissue and biomaterials are drawing a solid total of early-stage capital.
Despite orthopedic surgeons' conservative reputation when it comes to new technology adoption, high-tech devices are increasingly finding a place in this field. There have been recent developments in robotic computer-assisted surgery and other high-tech enabling tools that could lead to wider acceptance of these devices by surgeons better known in the past for eschewing such "frills." Although there are exceptions, most manufacturers seeking success in this market appear to have learned from the mistakes of the past, and many, instead of offering technology for technology's sake, are now trying to provide surgeons with what they really want - products that offer a value-added benefit to their practice.
All but dead a half a dozen years ago, MAKO Surgical is alive and well with an innovative technology platform that both embraces robotics and looks past it. Key to MAKO's strategy: a focus on unicompartmental knee procedures that are extremely difficult to do manually but, company officials hope, are significantly enabled by its robotic arm platform. If company officials are right, MAKO's robotics system could help explode the unicompartmental segment of the knee market without cannibalizing the total knee replacement segment. This year's AAOS meeting was a kind of coming out party for MAKO, whose major challenge now is convincing surgeons that robotics is more than just an intriguing gadget-it's a critical part of the surgical armamentarium
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
- Large Molecule